Article Figures & Data
Figures
- Fig 1.
Experimental design showing the timeline of each group for U87 glioma cell inoculation, bevacizumab therapy, MR imaging, and sacrifice for brain harvest.
- Fig 2.
Quantification of tumor volume and perfusion parameters in all tumors. T2WI and perfusion maps were acquired from a rat belonging to the 10-day treatment group. Serial reductions in rCBV and rCBF based on DSC and CBF based on ASL are shown. Graphs in the right column show serial changes of tumor volume and perfusion parameters in all tumors. Scale units of rCBVDSC, rCBFDSC, and CBFASL are milliliters × 100 g−1, milliliters × 100 g−1 × min−1, and milliliters × 100 g−1 × min−1, respectively. Data are mean results from paired t tests (unpaired t tests). One asterisk indicates P < .05; 2 asterisks, P < .001; NS, not significant; nCBVDSC, nCBV based on DSC; nCBFDSC, nCBF based on DSC; nCBFASL, nCBF based on ASL.
- Fig 3.
Quantification of tumor volume, perfusion parameters, and MVA in tumors with available histology. T2WI and perfusion maps were acquired from rats in the control group, 3-day treatment group, or 10-day treatment group. Differences in rCBV and rCBF based on DSC, CBF based on ASL, and MVA are shown. Graphs in the right column show differences in the tumor volume and hemodynamic parameters and MVA. In the lower images, the tumors stained immunohistochemically with anti-CD34 show positive brown cytoplasmic staining of the endothelial area and vessel lumen. Scale units of rCBVDSC, rCBFDSC, and CBFASL are milliliters × 100 g−1, milliliters × 100 g−1 × min−1, and milliliters × 100 g−1 × min−1, respectively. P values were based on 1-way analyses of variances. One asterisk indicates a significant (P < .05) difference from the Scheffe post hoc multiple comparisons.
Tables
- Table 1:
Comparison of volume and perfusion parameters based on DSC and ASL MR imaging in all tumorsa
Variables 0 Days (n = 14) 3 Days (n = 10) 10 Days (n = 4) Paired t Test Unpaired t Test P Valueb P Valuec P Valued P Valueb P Valuec P Valued Volume (mm3) 40.0 (32.3–61.8) 91.9 (53.9–124.1) 203.7 (103.0–301.3) .015 .200 .117 .002 .090 .086 nCBVDSC 5.9 (5.7–6.3) 2.7 (2.4–2.9) 0.8 (0.6–1.4) <.001 .004 <.001 <.001 .002 .005 nCBFDSC 3.7 (3.2–4.0) 1.8 (1.4–2.2) 0.7 (0.6–1.0) <.001 .020 <.001 <.001 .075 .004 nCBFASL 1.7 (1.2–2.0) 0.3 (0.2–0.5) 0.1 (0.1–0.1) <.001 .041 <.001 .004 .029 .050 - Table 2:
Comparison and correlation of perfusion parameters based on DSC and ASL MR imaging with MVA in tumors with available histologya
Variables Control (n = 4) 3-Day Treatment (n = 6) 10-Day Treatment (n = 4) P Valueb Different Groupsc Volume (mm3) 51.9 (40.8–72.1) 99.7 (91.8–124.1) 203.7 (103.0–301.3) 0.066 nCBVDSC 6.0 (5.7–6.3) 2.4 (2.2–2.7) 0.8 (0.6–1.4) <.001 (Control) (3 days) (3 days) (10 days) (Control) (10 days) nCBFDSC 3.5 (3.3–3.7) 1.8 (1.5–1.9) 0.7 (0.6–1.0) <.001 (Control) (3 days) (Control) (10 days) nCBFASL 1.4 (1.0–1.7) 0.3 (0.2–0.5) 0.1 (0.1–0.1) 0.005 (Control) (3 days) (Control) (10 days) MVA (×10−2) 7.5 (6.9–7.9) 2.8 (2.3–3.3) 2.4 (1.9–2.9) <.001 (Control) (3 days) (Control) (10 days)
Jump to section
Related Articles
Cited By...
- No citing articles found.